Bavencio Intravenous200 mg Special Drug Use - results Survey (Curatively unresectable or metastatic renal cell carcinoma)

Bavencio Intravenous200 mg Special Drug Use - results Survey (Curatively unresectable or metastatic renal cell carcinoma) - Bavencio Special Drug Use-results Survey (Renal cell carcinoma)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039476

Enrollment

250

Registered

2020-02-13

Start date

2019-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Curatively unresectable or metastatic renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who received at least one dose of Bavencio for Curatively unresectable or metastatic renal cell carcinoma during the enrollment period.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Incidence of all Adverse drug reactions / all Adverse Events related to the Safety Specification	—

Secondary

Measure	Time frame
Effectiveness in terms of Best Overall Response and Overall Survival	—

Countries

Japan

Contacts

Public ContactTaito Ito

Merck Biopharma Co., Ltd. PMS Planning & Strategy, Medical Department

taito.ito@merckgroup.com03-6756-0805

Outcome results